Elicera Therapeutics Ab Stock Current Asset
| ELIC Stock | 2.59 0.07 2.78% |
Elicera Therapeutics AB fundamentals help investors to digest information that contributes to Elicera Therapeutics' financial success or failures. It also enables traders to predict the movement of Elicera Stock. The fundamental analysis module provides a way to measure Elicera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elicera Therapeutics stock.
Elicera |
Elicera Therapeutics AB Company Current Asset Analysis
Elicera Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Elicera Therapeutics AB has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Elicera Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (23.30) % | |||
| Current Valuation | 42.8 M | |||
| Shares Outstanding | 19.78 M | |||
| Shares Owned By Insiders | 62.87 % | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 106.48 X | |||
| Revenue | 587 | |||
| Gross Profit | 587 | |||
| EBITDA | (13.11 M) | |||
| Net Income | (13.12 M) | |||
| Book Value Per Share | 1.85 X | |||
| Cash Flow From Operations | (14.29 M) | |||
| Earnings Per Share | (0.86) X | |||
| Market Capitalization | 78.53 M | |||
| Total Asset | 54.74 M | |||
| Net Asset | 54.74 M |
About Elicera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elicera Therapeutics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elicera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elicera Therapeutics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elicera Stock Analysis
When running Elicera Therapeutics' price analysis, check to measure Elicera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicera Therapeutics is operating at the current time. Most of Elicera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicera Therapeutics' price. Additionally, you may evaluate how the addition of Elicera Therapeutics to your portfolios can decrease your overall portfolio volatility.